Estimated Cancer Prevalence by Cancer Site and Gender, New York State, 2020
Source: New York State Cancer Registry
Site of Cancer | Diagnosed in Last 5 Years | Ever Diagnosed | ||||
---|---|---|---|---|---|---|
Males and Females | Males | Females | Males and Females | Males | Females | |
All Invasive Malignant Tumors | 400,900 | 194,900 | 206,000 | 1155500 | 530,300 | 625,200 |
Oral cavity and pharynx | 10,000 | 6,700 | 3,200 | 25,600 | 16,400 | 9,100 |
Esophagus | 2,100 | 1,600 | 500 | 4,000 | 2,900 | 1,100 |
Stomach | 5,500 | 3,100 | 2,400 | 13,100 | 7,200 | 5,800 |
Colorectal | 30,900 | 15,900 | 14,900 | 95,700 | 46,500 | 49,200 |
Liver / intrahepatic bile duct | 4,400 | 3,100 | 1,300 | 8,100 | 5,700 | 2,500 |
Pancreas | 5,200 | 2,600 | 2,600 | 8,200 | 4,000 | 4,200 |
Larynx | 2,600 | 2,100 | 600 | 7,800 | 6,100 | 1,700 |
Lung and bronchus | 31,400 | 13,700 | 17,700 | 54,700 | 23,500 | 31,200 |
Melanoma of the skin | 18,300 | 10,300 | 8,000 | 57,000 | 29,200 | 27,700 |
Female breast | 74,500 | 251,000 | ||||
Cervix uteri | 3,200 | 18,600 | ||||
Corpus uterus and NOS | 17,400 | 57,900 | ||||
Ovary | 4,800 | 17,200 | ||||
Prostate | 70,800 | 227,600 | ||||
Testis | 2,800 | 16,000 | ||||
Urinary bladder (incl. in situ) | 20,600 | 15,500 | 5,100 | 56,800 | 41,300 | 15,500 |
Kidney and renal pelvis | 16,200 | 10,400 | 5,800 | 44,300 | 27,400 | 16,900 |
Brain and other central nervous system | 3,400 | 1,800 | 1,500 | 13,100 | 6,800 | 6,300 |
Thyroid | 19,400 | 5,000 | 14,400 | 70,000 | 16,100 | 53,900 |
Hodgkin lymphoma | 2,800 | 1,500 | 1,300 | 16,100 | 8,200 | 7,800 |
Non-Hodgkin lymphomas | 19,000 | 9,900 | 9,000 | 55,000 | 28,500 | 26,500 |
Myeloma | 7,300 | 3,900 | 3,300 | 13,700 | 7,200 | 6,500 |
Leukemias | 12,500 | 7,300 | 5,200 | 35,500 | 20,000 | 15,500 |
Notes
- Estimated number of residents alive as of January 1, 2020, diagnosed with cancer within the last 5 years or anytime in the past, respectively.
- Numbers are rounded to the nearest 100.
- Refer to https://www.naaccr.org/wp-content/uploads/2020/01/CINA12-16.v5.sec1_.pdf for a detailed description of prevalence methodology.